Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

Carlo Visco(University of Verona), Ken H. Young(Duke Medical Center), Michael Møller(Hospital South West Jutland), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Maurilio Ponzoni(San Raffaele University of Rome), S. Dirnhofer(University Hospital of Basel), Y. C. Tai, B. S. Kahl(UW Health University Hospital), W.-m. Liu, E. D. His(Cleveland Clinic), Ronald S. Go(Mayo Clinic), J. Han van Krieken(Radboud University Nijmegen), Zijun Y. Xu‐Monette(Duke University), Qin Huang(City Of Hope National Medical Center), Emanuele S. G. d'Amore(Ospedale San Bortolo), Attilio Orazi(Texas Tech University), Alexandar Tzankov(University of Basel), Weiyun Z. Ai(University of California, San Francisco), April Chiu(Mayo Clinic), Roberto N. Miranda(The University of Texas MD Anderson Cancer Center), H.-Y. Wang(University of California San Diego), Y. Zu(Methodist Hospital), C. H. Dunphy(University of North Carolina at Chapel Hill), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Santiago Montes‐Moreno(Universidad de Cantabria), Liyun Wu(Roche (Switzerland)), S. O'Neill(University of North Carolina at Chapel Hill), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), W. W. Choi(University of Hong Kong), Yanping Li(Zhejiang Chinese Medical University), L. Jeffrey Medeiros(Delaware Division of Libraries), X. Frank Zhao(University of Maryland, Baltimore), Jane N. Winter(Northwestern University)
Haematologica
August 28, 2012
Cited by 165


Related Papers